<DOC>
	<DOC>NCT00548067</DOC>
	<brief_summary>The purpose of this study is to determine potential pharmacokinetic drug-drug interaction when three drugs (valsartan, amlodipine, and hydrochlorothiazide) are co-administered.</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients diagnosed as hypertensive Untreated confirmed hypertensive patients (consistent SBP &gt;140 mm Hg or DBP &gt;90 mm Hg) Uncontrolled hypertensive patients (Consistent SBP &gt;140 mm Hg or DBP &gt;90 mm Hg) on one drug therapy. Uncontrolled hypertensive patients (Consistent SBP &gt;140 mm Hg or DBP &gt;90 mm Hg) on two drug therapy. Inability to switch from all prior antihypertensive medications safely as required by the protocol. Need for drugs other than study drugs at the time of baseline. Patients with SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg at screening. Patients on four or more antihypertensive drugs at screening. Pregnant or nursing (lactating) women. Patients with diabetes mellitus Patients with heart diseases and any other disease Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>High blood pressure, hypertension, drug interaction, steady state, valsartan, hydrochlorothiazide, amlodipine</keyword>
</DOC>